Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain

Authors:

Abstract
Despite multi-modal analgesic techniques, acute postoperative pain remains an unmet health need, with up to three quarters of people undergoing surgery reporting significant pain. Liposomal bupivacaine is an analgesic consisting of bupivacaine hydrochloride encapsulated within multiple, non-concentric lipid bi-layers offering a novel method of sustained-release analgesia. To assess the analgesic efficacy and adverse effects of liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain. On 13 January 2016 we searched CENTRAL, MEDLINE, MEDLINE In-Process, Embase, ISI Web of Science and reference lists of retrieved articles. We obtained clinical trial reports and synopses of published and unpublished studies from Internet sources, and searched clinical trials databases for ongoing trials. Randomised, double-blind, placebo- or active-controlled clinical trials in people aged 18 years or over undergoing elective surgery, at any surgical site, were included if they compared liposomal bupivacaine infiltration at the surgical site with placebo or other type of analgesia. Two review authors independently considered trials for inclusion, assessed risk of bias, and extracted data. We performed data analysis using standard statistical techniques as described in the Cochrane Handbook for Systematic Reviews of Interventions, using Review Manager 5.3. We planned to perform a meta-analysis and produce a 'Summary of findings' table for each comparison however there were insufficient data to ensure a clinically meaningful answer. As such we have produced two 'Summary of findings' tables in a narrative format. Where possible we assessed the quality of evidence using GRADE. We identified nine studies (10 reports, 1377 participants) that met inclusion criteria. Four Phase II dose-escalating/de-escalating trials, designed to evaluate and demonstrate efficacy and safety, presented pooled data that we could not use. Of the remaining five parallel-arm studies (965 participants), two were placebo controlled and three used bupivacaine hydrochloride local anaesthetic infiltration as a control. Using the Cochrane tool, we judged most studies to be at unclear risk of bias overall; however, two studies were at high risk of selective reporting bias and four studies were at high risk of bias due to size (fewer than 50 participants per treatment arm). Three studies (551 participants) reported the primary outcome cumulative pain intensity over 72 hours following surgery. Compared to placebo, liposomal bupivacaine was associated with a lower cumulative pain score between the end of the operation (0 hours) and 72 hours (one study, very low quality). Compared to bupivacaine hydrochloride, two studies showed no difference for this outcome (very low quality evidence), however due to differences in the surgical population and surgical procedure (breast augmentation versus knee arthroplasty) we did not perform a meta-analysis. No serious adverse events were reported to be associated with the use of liposomal bupivacaine and none of the five studies reported withdrawals due to drug-related adverse events (moderate quality evidence). One study reported a lower mean pain score at 12 hours associated with liposomal bupivacaine compared to bupivacaine hydrochloride, but not at 24, 48 or 72 hours postoperatively (very low quality evidence). Two studies (382 participants) reported a longer time to first postoperative opioid dose compared to placebo (low quality evidence). Two studies (325 participants) reported the total postoperative opioid consumption over the first 72 hours: one study reported a lower cumulative opioid consumption for liposomal bupivacaine compared to placebo (very low quality evidence); one study reported no difference compared to bupivacaine hydrochloride (very low quality evidence). Three studies (492 participants) reported the percentage of participants not requiring postoperative opioids over initial 72 hours following surgery. One of the two studies comparing liposomal bupivacaine to placebo demonstrated a higher number of participants receiving liposomal bupivacaine did not require postoperative opioids (very low quality evidence). The other two studies, one versus placebo and one versus bupivacaine hydrochloride, found no difference in opioid requirement (very low quality evidence). Due to significant heterogeneity between the studies (I2 = 92%) we did not pool the results. All the included studies reported adverse events within 30 days of surgery, with nausea, constipation and vomiting being the most common. Of the five parallel-arm studies, none performed or reported health economic assessments or patient-reported outcomes other than pain. Using GRADE, the quality of evidence ranged from moderate to very low. The major limitation was the sparseness of data for outcomes of interest. In addition, a number of studies had a high risk of bias resulting in further downgrading. Liposomal bupivacaine at the surgical site does appear to reduce postoperative pain compared to placebo, however, at present the limited evidence does not demonstrate superiority to bupivacaine hydrochloride. There were no reported drug-related serious adverse events and no study withdrawals due to drug-related adverse events. Overall due to the low quality and volume of evidence our confidence in the effect estimate is limited and the true effect may be substantially different from our estimate. 外科手术部分的布比卡因脂质体浸润用于管理术后疼痛 尽管存在多种止痛技术,术后的急性疼痛仍是一个未能解决的健康问题,手术病人达3/4者报告有显著的疼痛。脂质体载布比卡因是一种由布比卡因盐酸盐及包裹其上的多层的、非同心圆状脂质双层结构组成的止痛剂,同时也是一种新方法的缓释止痛剂。 评价在手术部位利用脂质体布比卡因渗透来管理术后疼痛的疗效和副作用。 2016年1月13日,我们检索了CENTRAL, MEDLINE, MEDLINE In-Process, Embase, ISI Web of Science数据库及检索获得文章中的参考文献。我们从互联网资源中获取了公开和未公开发表的临床试验报告,并检索了临床试验数据库中正进行的试验。 纳入了以18岁及以上选择性手术人群作为研究对象的随机化、双盲、安慰剂或标准治疗对照且与安慰剂或其它类型止痛剂比较手术部位使用脂质体载布比卡因渗透的止痛效果的临床试验。 两名综述作者独立考虑可纳入的试验、评价偏倚风险和提取数据。我们利用Review Manager 5.3版中的《Cochrane手册之干预的系统性综述》(the Cochrane Handbook for Systematic Reviews of Interventions)中描述的标准的统计技术进行数据分析。我们计划进行一项meta-分析并对每一项比较得出一个结果汇总表,但缺乏足够的数据确保获得一个有临床意义的结果。鉴于此,我们得到了一个描述性的结果汇总表。有可能时我们使用GRADE评价了证据的质量。 我们发现9项研究(10篇报告,1377名受试者)符合纳入标准。4项临床II期的剂量上调/下调试验,设计用于评价并显示疗效和安全性,提供的汇总数据我们无法使用。其余的5项平行分组的研究(965名受试者),2项是安慰剂对照的,3项在使用布比卡因盐酸盐局部渗透止痛作为对照。利用Cochrane的工具,我们判断绝大部分研究整体上是偏倚风险未知;但2项研究是高选择性偏倚风险,4项研究因样本量(每个治疗组不足50名参与者)也高偏倚风险。 三项研究(551名参与者)报告了术后72小时中疼痛强度持续增加的主要结局。与安慰剂相比,脂质体载布比卡因观察期内(手术结束时0小时和术后72小时)与更低的疼痛评分持续增加相关(一项研究,证据质量很低)。与布比卡因盐酸盐相比,两项研究显示该结局没有差别(很低的证据质量),但因手术人群和手术规程的差异(隆胸术与关节成形术)而未能进行meta-分析。 未观察到与使用脂质体载布比卡因相关的严重不良事件,5项研究均未报告有药物相关的不良事件引起的参与者退出(中度质量证据)。 一项究报告了一个与脂质载布比卡因相关的、比布比卡因盐酸盐更低的术后12小时的疼痛评分均值,但在术后24、48、72小时无差别(证据质量极低)。 两项研究(382名受试者)报告了(脂质体载布比卡因)比安慰剂组术后首次使用阿片类药物时间更迟(证据质量低)。 两项研究(325名受试者)报告了术后72小时内总的阿片类药物使用量:一项研究称与安慰剂组相比脂质体载布比卡因组的累积阿片类药物使用量更少(证据质量极低);一项研究称与布比卡因盐酸盐比没有差异(证据质量极低)。 三项研究(492名受试者)报告了术后最初72小时内不需要阿片类药物的参与者的百分比。一项研究比较了脂质体载布比卡因与安慰剂,显示接受脂质体载布比卡因者中更多人术后不需要阿片类药物(证据质量极低)。另两项研究,一项与安慰剂相比,一项与布比卡因盐酸盐相比,发现对阿片类药物的需求没有差异(证据质量极低)。因研究之间的明显异质性(I2=92%),我们未合并结果。 所有纳入的研究均报道了术后30天内的不良反应事件,最常见的是恶心、便秘和呕吐。在5项平行对照的研究中,未进行或报告健康经济学评价或病例自己报告的除疼痛以外的结果。 使用GRADE评估的证据质量为极低至中度质量。主要的不足是相关的结局数据稀少。此外,一些研究的偏倚风险很高导致了证据质量进一步下调。 与安慰剂相比,手术部位的脂质体载布比卡因未显示出减少术后疼痛,而且目前有限的证据无法显示其与布比卡因盐酸盐更优。未有与药物相关严重不良反应事件的报告,也没有因药物相关不良反应而提前终止的研究。总体上,因为证据质低和量少,我们对效应估计的可信度有限,真实的效应可能与我们的估计有很大差异。 译者:张国州(简体中文志愿者);审校:李迅(北京中医药大学循证医学中心)

This publication has 44 references indexed in Scilit: